prof. dr. Nanja van Geel

Journal Article
open access

A meta-analysis of the placebo response in vitiligo: Causes and consequences for the interpretation of clinical trials

Nanja van Geel, Marijn Speeckaert (UGent) , Reinhart Speeckaert (UGent) and Nanja van Geel (UGent)

(2023) PIGMENT CELL & MELANOMA RESEARCH.

Clinician‐reported outcome measures for the assessment of vitiligo : a scoping review

Nanja van Geel (UGent) , Jolien Duponselle (UGent) , Liesbeth Delbaere (UGent) , Sandrine Herbelet (UGent) , Viktoria Eleftheriadou, Khaled Ezzedine, Maxine Forman, Amit Garg, Iltefat H. Hamzavi, Julien Seneschal, et al.

(2023) JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 37(11). p.2231-2242

Add to list

Conference Paper
C3
open access

Prognostic value of the vitiligo disease activity signs

Liesbeth Delbaere (UGent) , Jolien Duponselle (UGent) , Sandrine Herbelet (UGent) , Reinhart Speeckaert (UGent) and Nanja van Geel (UGent)

(2023) Belgian Dermatology Days 2023, Abstracts.

Add to list

Journal Article
A1
open access

Initiating value‐based healthcare in psoriasis : proposing a value‐based outcome set for daily clinical practice

Niels Hilhorst (UGent) , Elfie Deprez (UGent) , Deepak Mukesh Wieshwaykumar Balak, Nanja van Geel (UGent) , Jan Gutermuth, Isabelle Hoorens (UGent) and Jo Lambert (UGent)

(2023) JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY.

Add to list

Journal Article
A1
open access

Vitiligo International Task force for an Agreed List of core data (VITAL) : study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice

Nanja van Geel (UGent) , Iltefat H. Hamzavi, Amit G. Pandya, Albert Wolkerstorfer, Julien Seneschal, Amit Garg, Phyllis Spuls, Caroline B. Terwee, Sue Mallett, Reinhart Speeckaert (UGent) , et al.

(2022) TRIALS. 23(1).

Add to list

Biomarkers and clinical indicators of disease activity in vitiligo

Liesbeth Delbaere (UGent) , Reinhart Speeckaert (UGent) , Sandrine Herbelet (UGent) , Arno Belpaire (UGent) , Jolien Duponselle (UGent) and Nanja van Geel (UGent)

(2022) DERMATOLOGICAL REVIEWS. 3(5). p.289-307

Add to list

Credibility and generalization of the minimally important difference concept in dermatology : a scoping review

Reinhart Speeckaert (UGent) , Arno Belpaire (UGent) , Sandrine Herbelet (UGent) , Jo Lambert (UGent) and Nanja van Geel (UGent)

(2022) JAMA DERMATOLOGY. 158(11). p.1304-1314

Add to list

Journal Article
A1
open access

From IL-17 to IFN-γ in inflammatory skin disorders : is transdifferentiation a potential treatment target?

Arno Belpaire (UGent) , Nanja van Geel (UGent) and Reinhart Speeckaert (UGent)

(2022) FRONTIERS IN IMMUNOLOGY. 13.

Add to list

Journal Article
A1
open access

The meaning and reliability of minimal important differences (MIDs) for clinician-reported outcome measures (ClinROMs) in dermatology : a scoping review

Reinhart Speeckaert (UGent) , Arno Belpaire (UGent) , Sandrine Herbelet (UGent) , Marijn Speeckaert (UGent) and Nanja van Geel (UGent)

(2022) JOURNAL OF PERSONALIZED MEDICINE. 12(7).

Add to list

Image analysis systems to calculate the surface area of vitiligo lesions : a systematic review of measurement properties

Nanja van Geel (UGent) , Imke Saeys, Jérôme Van Causenbroeck, Jolien Duponselle (UGent) , Lynda Grine (UGent) , Nele Pauwels (UGent) , Niels Hilhorst (UGent) , Sandrine Herbelet (UGent) , Khaled Ezzedine and Reinhart Speeckaert (UGent)

(2022) PIGMENT CELL & MELANOMA RESEARCH. 35(5). p.480-494

Academic Bibliography

prof. dr. Nanja van Geel

A meta-analysis of the placebo response in vitiligo: Causes and consequences for the interpretation of clinical trials

Clinician‐reported outcome measures for the assessment of vitiligo : a scoping review

Prognostic value of the vitiligo disease activity signs

Initiating value‐based healthcare in psoriasis : proposing a value‐based outcome set for daily clinical practice

Vitiligo International Task force for an Agreed List of core data (VITAL) : study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice

Biomarkers and clinical indicators of disease activity in vitiligo

Credibility and generalization of the minimally important difference concept in dermatology : a scoping review

From IL-17 to IFN-γ in inflammatory skin disorders : is transdifferentiation a potential treatment target?

The meaning and reliability of minimal important differences (MIDs) for clinician-reported outcome measures (ClinROMs) in dermatology : a scoping review

Image analysis systems to calculate the surface area of vitiligo lesions : a systematic review of measurement properties

Contents

Support

Contact